[Erysipelatoid, angiectasic cancer of the breast. Mode of development].
D001943:Breast Neoplasms / Q000150:complications; D002277:Carcinoma / Q000188:drug therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008209:Lymphedema / Q000209:etiology; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D009639:Norethandrolone / Q000627:therapeutic use*; D011241:Prednisone / Q000627:therapeutic use; D013684:Telangiectasis / Q000188:drug therapy / Q000209:etiology; D014747:Vinblastine / Q000627:therapeutic use*
D014747:Vinblastine; D003520:Cyclophosphamide; D009639:Norethandrolone; D011241:Prednisone
Cancer du sein érysipélatoïde, angiectasique. Modalités évolutives.